1. (a) Gangjee, A., Elzein, E., Kothare, M., Vasudevan, A. Classical and nonclassical antifolates as potential antitumor, antipneumocystis and antitoxoplasma agents. Curr. Pharm. Des. 2: 263–280, 1996. (b) Berman, E.F., Werbel, L.M. The renewed potential for folate antagonists in contemporary cancer chemotherapy. J. Med. Chem. 34: 479-485, 1991. (c) Jackson, R.C. in Antifolate Drugs in Cancer Therapy, Jackman, A.L., ED., Humana Press: Totowa, NJ, pp. 1-12,1999.
2. Blakley, R. Eukaryotic dihydrofolate reductase. Adv.Enzymol.Mol.Biol.70: 23–102,1995.
3. Carreras, C.W., Santi, D.V. Catalytic mechanism and structure of thymidylate synthase. Annu. Rev. Biochem. 64: 721–762, 1995.
4. Kisliuk, R.L., Gaumont, Y., Powers, J.F., Thorndike, J., Nair, M.G., Piper, J.R. “Synergistic growth inhibition by combinations of antifolates.” In Evaluation of Folate Metabolism in Health and Disease, Picciano, M.F., Stokstad, E.L.R., Gregory, J.F., III, Eds., Alan R. Liss: New York, pp. 79–89, 1990.
5. Gangjee, A., Devraj, R., McGuire, J. J., Kisliuk, R. L. Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d] pyrimidines. J. Med. Chem. 38: 3798–3805, 1995.